Webcast: Antibody Drug Conjugates (ADCs)

This article provides key insights and suggested best practices for managed care to improve patient care in MPS disorders, which may also be relevant to other rare and ultra-rare conditions.

As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.

AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.